Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 5.1.99.4 extracted from

  • Scheil-Bertram, S.; Lorenz, D.; Ell, C.; Sheremet, E.; Fisseler-Eckhoff, A.
    Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barretts esophagus (2008), Mod. Pathol., 21, 961-967.
    View publication on PubMed

Application

Application Comment Organism
medicine in patients with early Barrett's adenocarcinoma treated with surgery, 91% of cases with low-grade dysplasia show immunoreactivity for alpha-methylacyl-CoA racemase, and 96% of case with high-grade dysplasia and early Barrett's adenocarcinoma are positive for alpha-methylacyl-CoA racemase Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
patients with early Barrett's adenocarcinoma treated with surgery
-

Source Tissue

Source Tissue Comment Organism Textmining
Barrett's epithelium epithelium that is negative for dysplasia and columnar epithelial cell changes indefinite for dysplasia does not demonstrate immunoreactivity for alpha-methylacyl-Coa racemase. Barrett's epithelium with columnar epithelial cell changes indefinite for dysplasia demonstrates alpha-methylacyl-Coa racemase immunoreactivity in 30% of cases Homo sapiens
-